| 2015 | | Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. | 정성현 |
| 2015 | | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | 강석윤 |
| 2013 | | Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). | 강석윤 |
| 2015 | | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. | 최진혁 |
| 2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial | 강석윤 |
| 2007 | | Neutrophilic eccrine hidradenitis in non-small cell lung cancer. | 김유찬 |
| 2013 | | Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. | 김도윤, 김영배, 서광욱, 오승엽 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2017 | | Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418) | 전미선 |
| 2015 | | Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2023 | | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | 정성현, 최윤석 |
| 2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
| 1997 | | P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. | 이기범 |
| 2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
| 2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
| 2017 | | PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma | 고영화, 한재호 |
| 2022 | | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 정성현, 최윤석 |
| 2014 | | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). | 정용식 |
| 2020 | | Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 | 안미선 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
| 2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
| 2007 | | Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. | - |
| 2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
| 2007 | | Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. | 장영주 |
| 2017 | | Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418) | 전미선 |
| 2005 | | Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. | 유희석, 이정필, 장기홍, 장혜진, 전미선 |
| 2019 | | Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey | 김선일, 추설호 |
| 2014 | | Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. | 김도윤, 김영배, 서광욱, 오승엽, 이제희 |
| 2015 | | Prevalence and characteristics of chemotherapy-related cognitive impairment in patients with breast cancer. | 박진희, 정용식 |
| 2021 | | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | 최진혁 |
| 2015 | | Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. | 고영화 |
| 2012 | | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 정성현 |
| 2017 | | Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study | 전미선 |
| 2017 | | Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy | 김영배, 노오규, 서광욱, 오승엽 |
| 2012 | | Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer | 유희석, 장석준 |
| 2016 | | Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma | 강대용, 안영실, 윤준기, 이수진, 이현우, 정성현 |
| 2016 | | Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer | 노오규, 오영택, 장석준, 전미선, 조오연 |
| 2016 | | Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma | 고영화 |
| 2015 | | Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). | 강석윤 |
| 2022 | | Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01) | 장석준 |
| 2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
| 2023 | | Radioimmunotherapy with 131I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma | 정성현 |
| 2015 | | Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. | 이현우 |
| 2020 | | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting | 이현우 |
| 2017 | | Re-evaluation of DNA Index as a Prognostic Factor in Children with Precursor B Cell Acute Lymphoblastic Leukemia | 노오규, 박준은, 정현주 |
| 2019 | | Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) | 장석준 |
| 2020 | | Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial | 장석준 |
| 2018 | | Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2022 | | Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model | 장석준 |
| 2019 | | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial | 강석윤 |
| 2023 | | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen | 안미선 |
| 2024 | | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | 이현우 |
| 2016 | | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF | 박준성 |
| 2014 | | Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells | 임인경, 최용원 |
| 2012 | | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial | 박준성 |
| 2012 | | Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells | 최경숙 |
| 2011 | | Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. | 정현주 |
| 2006 | | Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. | 김욱환, 최경숙 |
| 2022 | | Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial | 장석준 |
